Population clinical characteristics
| NACT (n=55) | CRT (n=52) | |
| Age (years) (median (IQR)) | 48 (40–58) | 45 (38–54) |
| Histology (n (%)) | ||
| Squamous cell carcinoma | 48 (87.2) | 46 (88.4) |
| Adenocarcinoma | 7 (12.7) | 5 (9.6) |
| Undifferentiated carcinoma | 0 (0) | 1 (1.9) |
| Stage (n (%)) | ||
| IIB | 24 (43.6) | 22 (42.3) |
| IIIA | 0 (0) | 1 (1.9) |
| IIIB | 26 (47.2) | 22 (42.3) |
| IVA | 5 (9.0) | 7 (13.4) |
| ECOG-PS (n (%)) | ||
| 0 | 25 (45.5) | 25 (48.0) |
| 1 | 30 (54.5) | 26 (50.0) |
| 2 | 0 (0) | 1 (1.9) |
| Lymph node (n (%)) | ||
| Positive | 23 (41.8) | 22 (42.3) |
| Negative | 32 (58.2) | 30 (57.6) |
| Hb level (g/dL) before CRT (median (range)) | 11.4 (10.7–12.3) | 11.9 (10.6–13.1) |
CRT, chemoradiation; ECOG-PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; IQR, interquartile range; NACT, neoadjuvant chemotherapy.